The Englewood, Colo.-based company said it sold a total of 11.5 million shares of stock at $3 per share, including shares sold during the full exercise of an underwriters option to purchase additional shares.
The total amount raised in the round was $32.4 million, after deducting underwriting discounts and commissions, Viveve said.
Net proceeds from the offering will support product commercialization, clinical research and development, for working capital and general corporate purposes, according to a press release.
Cowen acted as sole book-running manager for the offering, with Raymond James as lead manager and Ladenburg Thalmann and Maxim Group acting as co-managers, the company said.
Viveve’s flagship device is the Viveve System, which is designed as a non-surgical treatment for post-partum laxity of the vaginal introitus.
Last December, Viveve announced results from a sub-analysis of its Viveve 1 trial exploring the use of the Viveve system for treating vaginal introitus in women with sexual dysfunction, touting improvements on the Female Sexual Functions Index.
These featured panels at DeviceTalks Boston will explore the state of R&D at major medtech firms, as well as the latest trends when it comes to developing combination products, neuromodulation devices, robotic systems and women's health technology.
View Technology Track Featured Sessions
Register today to save. Use code TECHTRACK to save an additional 10%.